BioSpace News Archive

Two e-posters include new data across asthma and chronic obstructive pulmonary disease (COPD), emphasizing Teva’s commitment to patients with respiratory diseases

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company’s Board of Directors.

Top-line data from 643-subject Alzheimer’s disease pivotal GAIN Trial expected in fourth quarter 2021 Top-line data from 233-subject periodontal disease Phase 2 REPAIR sub-study of the GAIN Trial expected in fourth quarter 2021

Yale University, in partnership with Boehringer Ingelheim, today announced the launch of a Biomedical Data Science Fellowship program designed to attract and support some of the brightest and most innovative minds in data science from around the world.

Asia Green Biotechnology Corp. announced that InPlanta Biotechnology Ltd., the Company’s partner and licensor to it of various hemp and related agricultural products, has been granted its first full registration of a unique and proprietary hemp variety on Health Canada’s list of approved cultivars.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2021 investor call on Monday, May 17, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update.

Valneva SE announced that the underwriters of its global offering of an aggregate of 7,082,762 new ordinary shares, consisting of a public offering of 2,318,881 American Depositary Shares, each representing two ordinary shares, and a concurrent private placement of 2,445,000 ordinary shares in Europe and other countries outside of the United States, have exercised in full their option to purchase up to 1,062,414 additional new ordinary shares in the form of 531,207 ADSs.

BioNTech SE announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for south east Asia in Singapore.

Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year)

Over the years, biomedical researchers have increasingly focused on developing efficient and reliable methods for precise and targeted changes to virtually any point of genome of any living cell.